Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 427
- Registration Number
- NCT02027428
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Hematology and Oncology Associates, Inc., Canton, Ohio, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT02021500
- Locations
- 🇦🇺
Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia
🇫🇷Hôpital Beaujon, Clichy, France
🇺🇸Virginia Cancer Institute, Richmond, Virginia, United States
Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 83
- Registration Number
- NCT02017015
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳307 Hospital of Chinese PLA, Beijing, China
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT02011113
- Locations
- 🇯🇵
Celgene Trial Site, Tokyo, Japan
A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 50
- Registration Number
- NCT01999582
- Locations
- 🇩🇪
KfH Kuratorium für Dialyse und Nierentransplantation e.v., München, Germany
🇵🇹Nephrocare Faro, Faro, Portugal
🇵🇹Hospital de Santa Maria, Lisboa, Portugal
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Celgene
- Target Recruit Count
- 103
- Registration Number
- NCT01997840
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Local Institution - 201, Boston, Massachusetts, United States
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 503
- Registration Number
- NCT01996865
- Locations
- 🇺🇸
Local Institution - 011, Marietta, Georgia, United States
🇺🇸Local Institution - 056, Niles, Illinois, United States
🇺🇸Local Institution - 028, Park Ridge, Illinois, United States
A Phase 1 QT Study in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 72
- Registration Number
- NCT01986894
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Celgene
- Target Recruit Count
- 47
- Registration Number
- NCT01975610
- Locations
- 🇺🇸
NYU Langone Medical Center, New York, New York, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Family Arthritis Center, Jupiter, Florida, United States
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 866
- Registration Number
- NCT01964430
- Locations
- 🇺🇸
Local Institution - 016, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 023, Chattanooga, Tennessee, United States
🇺🇸Local Institution - 010, Dallas, Texas, United States